Cited 16 times in
Combination of a peroxisome proliferatoractivated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍그루 | - |
dc.contributor.author | 황기철 | - |
dc.contributor.author | 강석민 | - |
dc.contributor.author | 박성하 | - |
dc.contributor.author | 송병욱 | - |
dc.contributor.author | 심지영 | - |
dc.contributor.author | 이종은 | - |
dc.contributor.author | 정남식 | - |
dc.contributor.author | 하종원 | - |
dc.date.accessioned | 2015-01-06T17:29:40Z | - |
dc.date.available | 2015-01-06T17:29:40Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2040-1116 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100084 | - |
dc.description.abstract | AIMS/INTRODUCTION: We aimed to examine the effect of an angiotensin II receptor blocker (ARB), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, and their combination on myocardial fibrosis and function in type 2 diabetic rats. MATERIALS AND METHODS: Five male Long-Evans Tokushima Otsuka (LETO) rats and 20 male Otsuka Long-Evans Tokushima Fatty (OLETF) rats were used. OLETF rats were assigned to four groups (n = 5 per group) at 28 weeks-of-age: untreated, losartan-treated, rosiglitazone-treated and combination-treated. The ARB, losartan, was administered at a dose of 5 mg/kg/day, and the PPAR-gamma agonist, rosiglitazone, was administered at a dose of 3 mg/kg/day by oral gavage for 12 weeks. Urine and blood samples were collected, and two-dimensional echocardiograms and strain rate imaging were obtained at 28 and 40 weeks. Cytokines were evaluated by reverse transcriptase polymerase chain reaction, and histological analysis was carried out at 40 weeks. RESULTS: At 40 weeks, the global radial strains of the losartan-treated (55.7 ± 4.5%, P = 0.021) and combination-treated groups (59.3 ± 6.7%, P = 0.001) were significantly higher compared with the untreated OLETFs (44.3 ± 10.5%). No difference was observed when compared with LETO rats. Although the rosiglitazone-treated group showed a better metabolic profile than the untreated OLETF group, there was no difference in the global radial strain (49.8 ± 6.0 vs 44.3 ± 10.5, P = 0.402). The expression of pro-inflammatory cytokines, and collagen type I and III were consistently attenuated in the losartan-treated and combination-treated OLETF groups, but not in the rosiglitazone-treated group. CONCLUSIONS: A combination of rosiglitazone and losartan attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 362~371 | - |
dc.relation.isPartOf | JOURNAL OF DIABETES INVESTIGATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Combination of a peroxisome proliferatoractivated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chi Young Shim | - |
dc.contributor.googleauthor | Byeong-Wook Song | - |
dc.contributor.googleauthor | Min-Ji Cha | - |
dc.contributor.googleauthor | Ki-Chul Hwang | - |
dc.contributor.googleauthor | Sungha Park | - |
dc.contributor.googleauthor | Geu-Ru Hong | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.contributor.googleauthor | Jong Eun Lee | - |
dc.contributor.googleauthor | Jong-Won Ha | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.identifier.doi | 10.1111/jdi.12153 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04386 | - |
dc.contributor.localId | A04456 | - |
dc.contributor.localId | A00037 | - |
dc.contributor.localId | A01512 | - |
dc.contributor.localId | A02026 | - |
dc.contributor.localId | A02213 | - |
dc.contributor.localId | A03585 | - |
dc.contributor.localId | A04257 | - |
dc.contributor.localId | A03146 | - |
dc.relation.journalcode | J01377 | - |
dc.identifier.eissn | 2040-1124 | - |
dc.identifier.pmid | 25411595 | - |
dc.subject.keyword | Angiotensin II receptor blocker | - |
dc.subject.keyword | Diabetic cardiomyopathy | - |
dc.subject.keyword | Peroxisome proliferator‐activated receptor‐gamma agonist | - |
dc.contributor.alternativeName | Hong, Geu Ru | - |
dc.contributor.alternativeName | Hwang, Ki Chul | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.alternativeName | Park, Sung Ha | - |
dc.contributor.alternativeName | Song, Byeong Wook | - |
dc.contributor.alternativeName | Shim, Chi Young | - |
dc.contributor.alternativeName | Lee, Jong Eun | - |
dc.contributor.alternativeName | Chung, Nam Sik | - |
dc.contributor.alternativeName | Ha, Jong Won | - |
dc.contributor.affiliatedAuthor | Hong, Geu Ru | - |
dc.contributor.affiliatedAuthor | Hwang, Ki Chul | - |
dc.contributor.affiliatedAuthor | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | Park, Sung Ha | - |
dc.contributor.affiliatedAuthor | Song, Byeong Wook | - |
dc.contributor.affiliatedAuthor | Shim, Chi Young | - |
dc.contributor.affiliatedAuthor | Chung, Nam Sik | - |
dc.contributor.affiliatedAuthor | Ha, Jong Won | - |
dc.contributor.affiliatedAuthor | Lee, Jong Eun | - |
dc.citation.volume | 5 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 362 | - |
dc.citation.endPage | 371 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DIABETES INVESTIGATION, Vol.5(4) : 362-371, 2014 | - |
dc.identifier.rimsid | 50129 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.